“THE IMMUNE DOMINO
Cetuximab–EGFR engagement amplifies antitumor activity
01 NK cells kill cetuximab-tagged tumor cells
02 NK-derived IFN-γ activates dendritic cells
03 Dendritic cells present tumor antigens on MHC
04 IL-12 + IL-18 reactivate NK cells and macrophages
05 Macrophages engage cetuximab–EGFR complexes, releasing IFN-γ
06 Cytotoxic T cells and other immune cells activate; macrophage CXCL signals drive chemotaxis”
Biomedical Signal Map (DIY)